Form 4: Vir Biotechnology, Inc. (VIR), Rice Steven J., transaction 02/22/2022
Summary
This Vir Biotechnology, Inc. (VIR) Form 4 reports grants to Chief Administrative Officer Steven J. Rice on 02/22/2022: 20,000 restricted stock units under the issuer's Equity Incentive Plan and a stock option for 40,000 shares with a $29.48 exercise price and a 02/21/2032 expiration. Rice owned 38,658 shares directly after the award. Under the footnote, 25% of the option shares vest on February 22, 2023, and the rest in 36 equal monthly installments. The signature line reads /s/ Howard Horn, Attorney-in-Fact, 02/24/2022.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“Form 4: Vir Biotechnology, Inc. (VIR), Rice Steven J., transaction 02/22/2022.”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-vir-4-filed2022-02-24-0001209191-22-012953-6363fd2538/
, SHA-256 302672788c4e52aaeddf5ac3aae2b6ba668a9a30dbed0e56b72896cba1a06956.Full text
SEC Form 4 FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). 1. Name and Address of Reporting Person * Rice Steven J. (Last) (First) (Middle) C/O VIR BIOTECHNOLOGY, INC. 499 ILLINOIS STREET, SUITE 500 (Street) SAN FRANCISCO CA 94158 (City) (State) (Zip) | Rice Steven J. | (Last) | (First) | (Middle) | C/O VIR BIOTECHNOLOGY, INC. | 499 ILLINOIS STREET, SUITE 500 | SAN FRANCISCO | CA | 94158 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Vir Biotechnology, Inc. [ VIR ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Chief Administrative Officer | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | Chief Administrative Officer 3. Date of Earliest Transaction (Month/Day/Year) 02/22/2022 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code | V | Amount | (A) or (D) | Price Common Stock | 02/22/2022 | A (1) | 20,000 | A | $ 0.00 | 38,658 | D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares Stock Option (Right to Buy) | $ 29.48 | 02/22/2022 | A | 40,000 | (2) | 02/21/2032 | Common Stock | 40,000 | $ 0.00 | 40,000 | D Explanation of Responses: 1. Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. 2. 25% of the shares subject to the stock option vest and become exercisable on February 22, 2023, and the remainder vest in 36 equal monthly installments thereafter. Remarks: /s/ Howard Horn, Attorney-in-Fact | 02/24/2022 ** Signature of Reporting Person | Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
File and source
- File
- SEC_VIR_4_filed2022-02-24_0001209191-22-012953.xml
- Size
- 16,368 bytes
- SHA-256
- 302672788c4e52aaeddf5ac3aae2b6ba668a9a30dbed0e56b72896cba1a06956
- Original
- www.sec.gov